- Home
- WINA vs TARS Comparison
WINA vs TARS Comparison
Compare WINA & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WINA
- TARS
- Stock Information
- Founded
- WINA 1988
- TARS 2016
- Country
- WINA United States
- TARS United States
- Employees
- WINA N/A
- TARS N/A
- Industry
- WINA Other Specialty Stores
- TARS Medicinal Chemicals and Botanical Products
- Sector
- WINA Consumer Discretionary
- TARS Health Care
- Exchange
- WINA Nasdaq
- TARS Nasdaq
- Market Cap
- WINA 1.5B
- TARS 1.7B
- IPO Year
- WINA 1993
- TARS 2020
- Fundamental
- Price
- WINA $382.11
- TARS $40.95
- Analyst Decision
- WINA
- TARS Strong Buy
- Analyst Count
- WINA 0
- TARS 7
- Target Price
- WINA N/A
- TARS $67.14
- AVG Volume (30 Days)
- WINA 386.5K
- TARS 562.9K
- Earning Date
- WINA 07-16-2025
- TARS 08-07-2025
- Dividend Yield
- WINA 2.98%
- TARS N/A
- EPS Growth
- WINA 2.14
- TARS N/A
- EPS
- WINA 11.19
- TARS N/A
- Revenue
- WINA $83,099,300.00
- TARS $233,674,000.00
- Revenue This Year
- WINA $6.56
- TARS $122.94
- Revenue Next Year
- WINA $3.57
- TARS $44.14
- P/E Ratio
- WINA $33.31
- TARS N/A
- Revenue Growth
- WINA 0.33
- TARS 449.03
- 52 Week Low
- WINA $295.79
- TARS $20.08
- 52 Week High
- WINA $459.93
- TARS $57.28
- Technical
- Relative Strength Index (RSI)
- WINA 31.96
- TARS 40.57
- Support Level
- WINA $369.01
- TARS $39.33
- Resistance Level
- WINA $459.93
- TARS $42.00
- Average True Range (ATR)
- WINA 20.00
- TARS 1.73
- MACD
- WINA -9.50
- TARS 0.05
- Stochastic Oscillator
- WINA 0.00
- TARS 17.95
About WINA Winmark Corporation
Winmark Corp is a franchisor of value-oriented retail store concepts that buy, sell, and trade gently used merchandise. The company has one reportable segment including Franchising and one non-reportable segment Leasing. The franchising segment franchises value-oriented retail store that buys, sell, trade, and consign merchandise as well as provide strategic consulting services relating to franchising. The leasing segment includes middle-market equipment leasing business and small-ticket financing business. It generates a majority of its revenue from the Franchising segment.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.